Recent preclinical studies using the class I/II HDAC inhibitor zabadinostat (CXD101) demonstrated robust upregulation of MHC-I, MHC-II, and antigen processing machinery in CRC models, leading to increased CD8+ and CD4+ T cell infiltration. Here, HDAC9 is linked to colorectal carcinoma.